Last reviewed · How we verify
Iberet-Folic-500
Iberet-Folic-500 is a hematinc supplement combining iron and folic acid to treat and prevent nutritional anemia and folate deficiency.
Iberet-Folic-500 is a hematinc supplement combining iron and folic acid to treat and prevent nutritional anemia and folate deficiency. Used for Iron deficiency anemia, Folic acid deficiency, Anemia in pregnancy.
At a glance
| Generic name | Iberet-Folic-500 |
|---|---|
| Sponsor | University of Malaya |
| Drug class | Hematinc supplement / Nutritional supplement |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nutritional deficiency |
| Phase | FDA-approved |
Mechanism of action
The drug provides ferrous iron to replenish depleted iron stores and restore hemoglobin synthesis, while folic acid (vitamin B9) supports red blood cell formation and DNA synthesis. Together, these micronutrients address the dual deficiencies commonly seen in nutritional anemias, particularly in pregnancy and in populations with inadequate dietary intake.
Approved indications
- Iron deficiency anemia
- Folic acid deficiency
- Anemia in pregnancy
- Nutritional anemia prevention and treatment
Common side effects
- Gastrointestinal upset (nausea, constipation, abdominal discomfort)
- Dark stools
- Metallic taste
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iberet-Folic-500 CI brief — competitive landscape report
- Iberet-Folic-500 updates RSS · CI watch RSS
- University of Malaya portfolio CI